Role of activin in cell proliferation, differentiation, and carcinogenesis in the prostate and kidney
激活素在前列腺和肾脏细胞增殖、分化和癌变中的作用
基本信息
- 批准号:17591665
- 负责人:
- 金额:$ 1.66万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Activins are multifunctional growth and differentiation factors, and stimulate follicle-stimulating hormone (FSH)-β gene expression and FSH secretion by the pituitary gonadotropes. Follistatins bind activin, resulting in the neutralization of activin bioactivity. Activin/follistatin system is present in the prostate tissue. Prostate specific antigen (PSA) plays an important role in male reproductive physiology as well as is very important as a tumor marker for prostate cancer. Thus, the regulation of PSA has important clinical implications. Previsous studies showed that PSA is primarily regulated by andorogens. In the previous study, we evaluated the direct effects of activin A on the proliferation and PSA production of prostate cancer LNCaP cells, which functional activin receptors and androgen receptor, and PSA. LNCaP cells were treated with activin A, 5α-dihydrotestosterone (DHT) with or without their antagonists (follistatin, or nonsteroidal antiandrogen bicalutamide). Activin A de … More creased cell growth of LNCaP cells in a dose-dependent manner while DHT increased in a biphasic manner. In contrast to their opposing actions on the cell growth, both activin A and DHT up-regulated PSA gene expression and increased PSA secretion by LNCaP cells. The effects of activin A and DHT to increase PSA production were synergistic or additive. Follistatin or bicalutamide was without effect on cell growth or PSA production. The effects of activin A on LNCaP cells were blocked by follistatin, not by bicalutamide, while those of DHT were prevented by bicalutamide, not by follistatin. Activin A up-regulates PSA production and the effect is through androgen receptor independent pathway. Activin/follistatin system can be a physiological modulator of PSA gene transcription and secretion in the prostate tissue, and activins may cooperate with androgen to up-regulate PSA in vivo.In the present study, we have shown that activin completely inhibited the proliferation of LNCaP cells in the absence of androgens, and after one week treatment of activin, androgen never recovered the proliferation of the cells. Differentiation markers including PSA suggested that activin induced the non-reversible differentiation of the cells. Further, activin slightly inhibited the growth of LNCaP cells in vivo models.Further, in another experiment, we have shown that glucocorticoids, at concentrations achievable in vivo by oral administration of low doses of DEX, have an inhibitory effect on vascular endothelial growth factor (VEGF) and IL8 mRNA expression and protein secretion of prostate cells possibly through the glucocorticoid receptor pathway, and suppress in vivo tumor growth. Less
激活素是一种多功能的生长和分化因子,可刺激促卵泡激素(FSH)-β基因表达和垂体促性腺激素分泌。卵泡抑素结合激活素,导致激活素生物活性的中和。激活素/卵泡抑素系统存在于前列腺组织中。前列腺特异性抗原(PSA)在男性生殖生理中起重要作用,同时也是前列腺癌的重要肿瘤标志物。因此,PSA的调节具有重要的临床意义。以往的研究表明,PSA主要受雄激素的调节。在先前的研究中,我们评估了激活素A对前列腺癌LNCaP细胞增殖和PSA产生的直接影响,LNCaP细胞具有功能性激活素受体和雄激素受体,以及PSA。LNCaP细胞用激活素A、5α-二氢睾酮(DHT)和或不和其拮抗剂(卵泡抑素或非甾体抗雄激素比卡鲁胺)处理。激活素A de ...更多信息 以剂量依赖性方式增加LNCaP细胞的细胞生长,而DHT以双相方式增加。与它们对细胞生长的相反作用相反,激活素A和DHT均上调PSA基因表达并增加LNCaP细胞的PSA分泌。激活素A和DHT增加PSA产生的作用是协同的或相加的。卵泡抑素或比卡鲁胺对细胞生长或PSA产生没有影响。激活素A对LNCaP细胞的作用被卵泡抑素阻断,而不是被比卡鲁胺阻断,而DHT的作用被比卡鲁胺阻断,而不是被卵泡抑素阻断。激活素A通过雄激素受体非依赖性途径上调PSA的产生。激活素/卵泡抑素系统可能是前列腺组织PSA基因转录和分泌的生理调节因子,激活素可能与雄激素协同上调体内PSA,本研究表明,在无雄激素存在下,激活素可完全抑制LNCaP细胞的增殖,且在激活素处理一周后,雄激素不能恢复LNCaP细胞的增殖。PSA等分化标志物提示激活素诱导细胞的不可逆分化。此外,在另一个实验中,我们已经表明,糖皮质激素,在体内通过口服低剂量的DEX可达到的浓度下,可能通过糖皮质激素受体途径对前列腺细胞的血管内皮生长因子(VEGF)和IL 8 mRNA表达和蛋白分泌具有抑制作用,并抑制体内肿瘤生长。少
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells
- DOI:10.1158/1078-0432.ccr-06-0749
- 发表时间:2006-10-15
- 期刊:
- 影响因子:11.5
- 作者:Yano, Akihiro;Fujii, Yasuhisa;Kihara, Kazunori
- 通讯作者:Kihara, Kazunori
Deferred combined androgen blockage therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy
在雄激素剥夺单一疗法期间使用比卡鲁胺对激素难治性前列腺癌患者进行延迟联合雄激素阻断治疗
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Fujii Y;Kihara K;et al.
- 通讯作者:et al.
Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract
- DOI:10.1111/j.1464-410x.2006.06158.x
- 发表时间:2006-06-01
- 期刊:
- 影响因子:4.5
- 作者:Ohtsuka, Yukihiro;Kawakami, Satoru;Kihara, Kazunori
- 通讯作者:Kihara, Kazunori
Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy
在雄激素剥夺单一疗法期间使用比卡鲁胺对激素难治性前列腺癌患者进行延迟联合雄激素阻断治疗
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Fujii Y;Kihara K;et al.
- 通讯作者:et al.
Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells
- DOI:10.1158/1078-0432.ccr-05-2085
- 发表时间:2006-05-15
- 期刊:
- 影响因子:11.5
- 作者:Yano, Akihiro;Fujii, Yasuhisa;Kihara, Kazunori
- 通讯作者:Kihara, Kazunori
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIHARA Kazunori其他文献
KIHARA Kazunori的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIHARA Kazunori', 18)}}的其他基金
Reconstruction of the autonomic nerves controlling the pelvic organs and its clinical application
控制盆腔器官的自主神经重建及其临床应用
- 批准号:
14370504 - 财政年份:2002
- 资助金额:
$ 1.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Reconstruction of the autonomic nerve controlling urogenital tract and its clinical application
控制泌尿生殖道的自主神经重建及其临床应用
- 批准号:
12671521 - 财政年份:2000
- 资助金额:
$ 1.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Reconstruction of injured autonomic nerves in the abdominal and pelvic spaces.
重建腹部和骨盆空间受损的自主神经。
- 批准号:
09470341 - 财政年份:1997
- 资助金额:
$ 1.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似国自然基金
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
- 批准号:82370979
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
BRD4通过结合TEAD1调控β细胞增殖分化的机制研究
- 批准号:82370801
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
生理/病理应激差异化调控肝再生的“蓝斑—中缝”神经环路机制
- 批准号:82371517
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
新生儿坏死性小肠结肠炎中去泛素化酶USP15调控ILC3分化损伤肠道粘膜屏障的致病机制研究
- 批准号:82371711
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
- 批准号:82370906
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
组蛋白乙酰化修饰ATG13激活自噬在牵张应力介导骨缝Gli1+干细胞成骨中的机制研究
- 批准号:82370988
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
LIPUS促进微环境巨噬细胞释放CCL2诱导尿道周围平滑肌祖细胞定植与分化的机制研究
- 批准号:82370780
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
TNFAIP8/Hippo/SIX1轴调控软骨干细胞分化能力在颞下颌骨关节炎中的机制研究
- 批准号:82370980
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
转录因子CEBPE调控不同亚型AML细胞分化机制及靶向治疗研究
- 批准号:32000497
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
中性粒细胞在体内条件下重编程为造血干祖细胞的研究
- 批准号:92068101
- 批准年份:2020
- 资助金额:80.0 万元
- 项目类别:重大研究计划
相似海外基金
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities
烯醇化酶在前列腺癌健康差异中的作用和治疗潜力
- 批准号:
10649164 - 财政年份:2023
- 资助金额:
$ 1.66万 - 项目类别:
Project: Survivorship Care Physical Activity Initiative to Improve Disparities in HRQoL for Prostate Cancer Survivors (RELate Study)
项目:旨在改善前列腺癌幸存者 HRQoL 差异的生存护理体力活动计划(RELate 研究)
- 批准号:
10911646 - 财政年份:2023
- 资助金额:
$ 1.66万 - 项目类别:
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
“DNMT 和 TET1 重编程作为晚期前列腺癌的靶向耐药机制”
- 批准号:
10681632 - 财政年份:2023
- 资助金额:
$ 1.66万 - 项目类别:
BCC for Prostate Cancer: Discovery and Translation of Biomarkers for Clinical Unmet Needs
前列腺癌的 BCC:发现和转化生物标志物以满足临床未满足的需求
- 批准号:
10701245 - 财政年份:2023
- 资助金额:
$ 1.66万 - 项目类别:
Project 1: Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer
项目1:高危前列腺癌转移级联的肿瘤微环境启动因素
- 批准号:
10555400 - 财政年份:2023
- 资助金额:
$ 1.66万 - 项目类别:
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes
根据循环肿瘤 DNA 评估前列腺癌表型和基因型分类作为预测治疗结果的生物标志物
- 批准号:
10804464 - 财政年份:2023
- 资助金额:
$ 1.66万 - 项目类别:
Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis
项目2:研究前列腺癌骨转移的细胞内在和外在驱动因素
- 批准号:
10333944 - 财政年份:2022
- 资助金额:
$ 1.66万 - 项目类别:
Investigating cell-intrinsic and extrinsic interactions in prostate cancer at the single cell level
在单细胞水平上研究前列腺癌的细胞内在和外在相互作用
- 批准号:
10612346 - 财政年份:2022
- 资助金额:
$ 1.66万 - 项目类别:
RET Regulation and Targeting in Neuroendocrine Prostate Cancer
神经内分泌前列腺癌中的 RET 调节和靶向
- 批准号:
10419078 - 财政年份:2022
- 资助金额:
$ 1.66万 - 项目类别: